Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.62 |
| ▸ | MAOA | P21397 | 7/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.62 |
| ▸ | SDHA | P31040 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CALML3 | P27482 | 1/20 | 0.62 |
| ▸ | F10 | P00742 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12478379 | 1.00 | MAOB (0.62) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL12006681 | 1.00 | MAOB (0.62) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL28109804 | 0.88 | LMNA (0.52) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL12478380 | 0.85 | MAOB (0.69) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL17026089 | 0.85 | MAOB (0.69) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL10038893 | 0.85 | MAOB (0.62) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL10038450 | 0.85 | MAOB (0.69) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL17975540 | 0.85 | MAOB (0.49) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL8863155 | 0.85 | MAOB (0.47) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL18396815 | 0.85 | MAOB (0.56) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107923-A1 | WATER-SOLUBLE O-CARBONYL PHOSPHORAMIDATE PRODRUGS FOR THERAPEUTIC ADMINISTRATION | Micurx Pharmaceuticals, Inc. (US) | 2016-12-28 | — | — | EP | claimed |
| US-9382276-B2 | Water-soluble O-carbonyl phosphoramidate prodrugs for therapeutic administration | MICURX PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | claimed |
| WO-2015127316-A1 | WATER-SOLUBLE O-CARBONYL PHOSPHORAMIDATE PRODRUGS FOR THERAPEUTIC ADMINISTRATION | MICURX PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20150239922-A1 | WATER-SOLUBLE O-CARBONYL PHOSPHORAMIDATE PRODRUGS FOR THERAPEUTIC ADMINISTRATION | SHANGHAI MICURX PHARMACEUTICAL CO. LTD. (CN) | 2015-08-27 | — | — | US | claimed |
| EP-3107923-B1 | WATER-SOLUBLE O-CARBONYL PHOSPHORAMIDATE PRODRUGS FOR THERAPEUTIC ADMINISTRATION | SHANGHAI MICURX PHARMACEUTICAL CO LTD (CN) | 2021-11-03 | — | — | EP | disclosed |
| EP-3107923-A1 | WATER-SOLUBLE O-CARBONYL PHOSPHORAMIDATE PRODRUGS FOR THERAPEUTIC ADMINISTRATION | Micurx Pharmaceuticals, Inc. (US) | 2016-12-28 | — | — | EP | disclosed |
| US-9382276-B2 | Water-soluble O-carbonyl phosphoramidate prodrugs for therapeutic administration | MICURX PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2015127316-A1 | WATER-SOLUBLE O-CARBONYL PHOSPHORAMIDATE PRODRUGS FOR THERAPEUTIC ADMINISTRATION | MICURX PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20150239922-A1 | WATER-SOLUBLE O-CARBONYL PHOSPHORAMIDATE PRODRUGS FOR THERAPEUTIC ADMINISTRATION | SHANGHAI MICURX PHARMACEUTICAL CO. LTD. (CN) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239922-A1 | WATER-SOLUBLE O-CARBONYL PHOSPHORAMIDATE PRODRUGS FOR THERAPEUTIC ADMINISTRATION | DPYD, SI, NUDT1 | MAOB 1186/4885MAOA 2019/4885PTGS1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.